cwf24 Antibody

What is CD24 and why is it a target for antibody development?

CD24 is a small, highly glycosylated protein overexpressed in many solid malignancies, making it a valuable cancer biomarker . It functions as a powerful anti-phagocytic "don't eat me" signal that can shield cancer cells from macrophage-mediated clearance, particularly macrophages expressing Siglec-10 . The protein plays a crucial role in tumor development through its involvement in several oncogenic signaling pathways, including Src/STAT3, EGFR, HER2, MAPK, AKT/mTOR, WNT/β-catenin, and miRNA-related pathways . These characteristics make CD24 an attractive target for cancer immunotherapy.

The rationale for developing antibodies against CD24 stems from its overexpression pattern in various solid tumors and hematologic cancers, combined with its immunosuppressive function . By blocking CD24 with targeted antibodies, researchers aim to prevent its interaction with Siglec-10, thereby restoring macrophage-mediated phagocytosis of cancer cells and enhancing anti-tumor immune responses . This approach positions CD24-targeting antibodies as a novel class of innate immune checkpoint inhibitors with significant therapeutic potential.

How are CD24 antibodies generated and what are their main types?

CD24 antibodies can be generated through multiple approaches, including both traditional hybridoma technology and recombinant antibody engineering. For humanized monoclonal antibodies like IMM47, researchers utilize internal CHO-K1 cell expression methods to produce antibodies with desired specificity and functional properties . The generation process typically involves immunizing animals (often mice) with purified antigen, followed by hybridoma creation or lymphocyte isolation for antibody gene cloning .

Several types of CD24 antibodies have been developed and investigated for their therapeutic potential:

• Full-length monoclonal antibodies (mAbs): Examples include IMM47 (humanized), ALB9, SWA11, ML-5, and G7, each with demonstrated anti-tumor effects in various cancer models .

• Recombinant antibody fragments: These include single-chain variable fragments (scFv), antigen-binding fragments (Fab), and single-chain variable fragments with truncated constant regions (scFvC) . These smaller formats offer advantages for specific applications where tissue penetration or rapid clearance is desired.

• Fusion proteins: CD24Fc is a recombinant fusion protein that stimulates the CD24/Siglec-10 pathway, which has been studied in clinical trials for patients with melanoma or advanced solid tumors .

The choice between these formats depends on the specific research or therapeutic application, with full-length antibodies generally preferred for standard indirect immunofluorescence, immunoblotting, and immunoprecipitation experiments due to their signal amplification capabilities .

What methods are used to assess binding affinity of anti-CD24 antibodies?

Researchers employ several methods to evaluate the binding affinity and specificity of anti-CD24 antibodies, with enzyme-linked immunosorbent assay (ELISA) being a primary technique. The ELISA methodology typically involves:

• Coating microplate wells with CD24 target antigens (which may include wild-type CD24 or mutant variants).

• Blocking with skim milk solution to prevent non-specific binding.

• Adding diluted antibody samples and allowing interaction.

• Detecting bound antibodies using enzyme-conjugated secondary antibodies.

• Developing with substrate solution and measuring optical density.

• Analyzing results with appropriate software to generate binding curves .

Flow cytometry represents another critical method for assessing CD24 antibody binding to cells. This approach allows researchers to determine whether antibodies selectively bind to CD24-positive cells while avoiding interaction with CD24-negative cells . Cross-binding studies using flow cytometry are particularly valuable for evaluating species specificity, as demonstrated with IMM47, which was found to bind only to human and chimpanzee CD24, not to CD24 from other species .

Additional binding characterization methods may include surface plasmon resonance (SPR) for real-time binding kinetics analysis and immunoblotting to confirm specificity against the target protein. For antibodies intended for tissue applications, immunohistochemistry provides critical information about binding patterns in biological samples. These complementary approaches collectively establish the binding profile of anti-CD24 antibodies, guiding their application in research and potential clinical development.

How does the CD24/Siglec-10 interaction impact immune evasion in cancer?

The CD24/Siglec-10 interaction represents a sophisticated immune evasion mechanism exploited by cancer cells. When CD24 on cancer cells binds to Siglec-10 on macrophages, it triggers an inhibitory signaling cascade that significantly suppresses phagocytic activity . Mechanistically, this interaction activates inhibitory SHP-1 and/or SHP-2 phosphatases, which subsequently dampen TLR-mediated inflammation and macrophage-induced cellular engulfment . This process effectively creates a "don't eat me" signal, allowing cancer cells to evade immune surveillance and clearance.

The CD24/Siglec-10 axis functions alongside other well-characterized immune checkpoint pathways. Cancer cells frequently overexpress multiple anti-phagocytic surface proteins, including CD47, programmed cell death ligand 1 (PD-L1), and the beta-2 microglobulin subunit of the major histocompatibility class I complex (B2M) . Together, these signals create a multifaceted immune suppressive microenvironment that protects tumor cells from macrophage-mediated elimination.

Research indicates that blocking the CD24/Siglec-10 interaction with antibodies like IMM47 can restore macrophage phagocytic function against cancer cells . This represents a novel approach to cancer immunotherapy that targets innate immune checkpoints rather than the adaptive immune checkpoints (like PD-1/PD-L1) that are the focus of many current immunotherapies. The distinct mechanism of action suggests potential for combinatorial approaches with existing checkpoint inhibitors, which has been demonstrated in preclinical models showing synergistic effects when CD24 antibodies are combined with PD-1 inhibitors like Tislelizumab, Opdivo, and Keytruda .

What role does N-glycosylation play in CD24 antibody binding?

N-glycosylation of CD24 represents a critical factor in its biological function and antibody recognition properties. CD24 is a heavily glycosylated protein, and these post-translational modifications significantly influence its interactions with binding partners, particularly Siglec-10 . Research indicates that Siglec-10 interacts primarily with the sialylated form of CD24, and experimental surface desialylation notably inhibits Siglec-10-Fc binding to CD24-expressing cells .

Interestingly, studies with IMM47 revealed that this humanized antibody can bind to CD24 regardless of N-glycosylation status of the extracellular domain . Specifically, researchers found that:

• Modifications of the extracellular domain's N-glycosylation had no detectable effect on IMM47's ability to bind to CD24 .

• Treatment of Reh cells (CD24-positive cells) with either N-glycosidase or sialidase actually improved their capacity to bind to IMM47 mAb .

These findings suggest that unlike Siglec-10, which requires sialylation for optimal binding, IMM47 recognizes protein epitopes rather than glycan structures on CD24. This glycosylation-independent binding profile represents an advantage for therapeutic applications, as it ensures consistent target recognition regardless of glycosylation heterogeneity that may exist across different tumor types or cell states. The property also highlights fundamental differences in how antibodies and natural binding partners recognize CD24, providing insights that can guide the rational design of next-generation CD24-targeting therapeutics.

How can researchers generate and diversify recombinant monoclonal antibodies against CD24?

Generating and diversifying recombinant monoclonal antibodies against CD24 involves several sophisticated techniques that allow researchers to create customized antibody formats for specific applications. The process typically begins with obtaining antibody variable region sequences, either through hybridoma sequencing or antibody discovery platforms .

For full-length antibody production, researchers can:

• Design DNA geneblocks encoding the heavy chain (HC) and light chain (LC) sequences, optimized for expression in human cells using codon optimization tools .

• Include appropriate signal peptide sequences in the geneblock design for proper secretion .

• Clone the resulting DNA fragments into expression vectors using methods like Gibson assembly .

• Co-express HC and LC plasmids in mammalian expression systems such as HEK293 suspension culture cells (Expi293F cells) .

• Purify secreted antibodies from cell culture supernatant using affinity chromatography methods like Protein A Sepharose columns .

To diversify antibody formats, researchers can generate several variations:

• scFvC (single chain variable fragment plus truncated constant region): Connect variable regions of HC and LC with a flexible linker, then attach to specific HC constant regions to create a single polypeptide chain (~60 kDa) .

• scFv (single chain variable fragment): Link only the variable regions of HC and LC without constant regions, creating a smaller antibody fragment .

• Fab (antigen binding fragment): Include variable regions plus one constant region of each chain .

• Species specificity swapping: Design geneblocks corresponding only to the variable regions and combine them with constant regions from different species to alter antibody functionality while maintaining target specificity .

These diversification approaches allow researchers to tailor CD24 antibodies for specific experimental needs, balancing factors such as tissue penetration, half-life, effector functions, and compatibility with other reagents in multiplexed assays.

What are the comparative advantages of different CD24 antibody formats for research applications?

Different CD24 antibody formats offer distinct advantages for specific research applications, with the choice dependent on experimental goals, technical requirements, and biological contexts. The following table summarizes the comparative advantages of various antibody formats:

For standard indirect immunofluorescence experiments, full-length bivalent antibodies are generally preferred because multiple secondary antibodies can bind to the constant regions, resulting in signal amplification and increased sensitivity . Similar advantages apply to immunoblotting and immunoprecipitation experiments.

Researchers working with CD24 antibodies should carefully consider these trade-offs when selecting the appropriate format for their specific experimental needs, taking into account factors such as the target accessibility, required sensitivity, and whether effector functions are beneficial or detrimental to the research objectives.

What techniques are used to evaluate the efficacy of CD24 antibodies in vitro?

Researchers employ several in vitro assays to evaluate the efficacy of CD24 antibodies like IMM47, focusing on both binding properties and functional activities. These techniques provide critical insights into antibody mechanisms of action and potential therapeutic efficacy:

• Antibody-Dependent Cellular Cytotoxicity (ADCC) Assays: These evaluate the ability of antibodies to engage immune effector cells (primarily NK cells) to kill antibody-coated target cells. For CD24 antibodies like IMM47, ADCC assays have demonstrated significant cytotoxic activity against CD24-positive cancer cells .

• Antibody-Dependent Cellular Phagocytosis (ADCP) Assays: These assess the capacity of antibodies to enhance macrophage-mediated phagocytosis of target cells. Since CD24 functions as a "don't eat me" signal, ADCP assays are particularly relevant for evaluating CD24 antibody efficacy .

• Antibody-Dependent Cellular Trafficking (ADCT): This measures the antibody's ability to facilitate antigen presentation and subsequent immune activation. IMM47 has demonstrated significant ADCT activity in preclinical studies .

• Complement-Dependent Cytotoxicity (CDC) Assays: These evaluate the ability of antibodies to activate the complement cascade, leading to target cell lysis. IMM47 has shown notable CDC activity in vitro .

• Blocking Assays: These assess the antibody's ability to block specific protein-protein interactions, such as CD24/Siglec-10 binding. For CD24 antibodies, these assays are critical for determining if the antibody can prevent the immunosuppressive signaling that inhibits macrophage function .

• Cytokine Release Assays: These measure whether the antibody can enhance immune cell activation, as evidenced by increased cytokine production. For CD24 antibodies, enhanced NK cell cytokine release indicates successful activation of anti-tumor immunity .

These comprehensive in vitro evaluations provide a multifaceted picture of CD24 antibody efficacy, informing subsequent in vivo studies and potential clinical development strategies. The collective results from these assays for IMM47 specifically have demonstrated exceptional anti-tumor activity through multiple mechanisms, highlighting its promise as a cancer immunotherapy agent .

How are CD24 antibodies tested in animal models?

Testing CD24 antibodies in animal models represents a critical step in evaluating their therapeutic potential. For antibodies like IMM47, researchers employ sophisticated in vivo approaches to assess efficacy, safety, and mechanism of action:

• Transgenic Mouse Models: Due to the species-specific binding of anti-human CD24 antibodies like IMM47 (which binds only to human and chimpanzee CD24, not mouse CD24), researchers develop transgenic mouse models expressing human CD24 to conduct meaningful studies . This approach ensures that the antibody can recognize its target in the model system.

• Pharmacodynamic Analysis: Researchers administer the CD24 antibody to appropriate animal models and evaluate various parameters including tumor growth inhibition, immune cell infiltration, and biomarker changes over time . For IMM47, such analyses revealed potent anti-tumor efficacy in transgenic mouse models .

• Memory Immune Response Assessment: Following treatment with CD24 antibodies, researchers evaluate whether animals develop a memory immune response that provides long-term protection against tumor rechallenge . Studies with IMM47 demonstrated establishment of such memory responses following therapy .

• Combination Therapy Studies: To assess potential synergistic effects, CD24 antibodies are evaluated in combination with other immunotherapeutic agents. For example, IMM47 has been tested in combination with various PD-1 antibodies (Tislelizumab, Opdivo, Keytruda), revealing synergistic therapeutic efficacy that exceeds the benefit of either agent alone .

• Safety Evaluations: Unlike some anti-CD47 antibodies that show toxicity due to binding to red blood cells (RBCs), CD24 antibodies like IMM47 are assessed for such off-target effects. IMM47 demonstrated a favorable safety profile as it does not bind to human RBCs .

These comprehensive in vivo evaluations provide critical data on CD24 antibody efficacy and safety in complex biological systems, serving as an essential bridge between in vitro studies and potential clinical trials. The positive results obtained for IMM47 in these animal models have supported progression to clinical development, with clinical trial applications submitted in Australia, the United States, and China .

How can researchers modify the species specificity of CD24 antibodies?

Modifying the species specificity of CD24 antibodies is a sophisticated approach that allows researchers to create versatile reagents for various experimental systems while maintaining target recognition. This process is particularly important for CD24 antibodies given the observed poor homology between human CD24 and CD24 from most other species (except chimpanzees) . The modification strategy typically involves:

• Variable Region Conservation: The first critical step is to maintain the variable regions (VH and VL) that contain the complementarity-determining regions (CDRs) responsible for antigen recognition. These regions determine the antibody's specificity for CD24 and must be preserved .

• Constant Region Swapping: Researchers can design geneblocks corresponding only to the variable regions of the heavy chains (HCs) and light chains (LCs), then combine these with constant regions from different species . For example:

  • Human variable regions can be combined with mouse constant regions to create a chimeric antibody that will be recognized by anti-mouse secondary antibodies

  • Rabbit variable regions can be combined with human constant regions to create antibodies detectable with anti-human reagents

• Cloning Strategy Implementation: The practical approach involves:

  • Generating PCR fragments corresponding to the target species constant regions for both HCs and LCs

  • Using Gibson assembly or similar cloning methods to join variable and constant region sequences

  • Inserting appropriate signal peptides for proper secretion

  • Co-transfecting the modified HC and LC plasmids into expression cells

• Expression and Purification: The modified antibodies are expressed in mammalian cells (typically Expi293F cells) and purified using appropriate affinity chromatography methods such as Protein A Sepharose columns .

This approach allows researchers to retain the CD24-binding properties of the original antibody while gaining flexibility in experimental design. For instance, antibodies with different species specificities can be used simultaneously in co-localization studies, with each antibody detectable by species-specific secondary antibodies . This technique expands the toolbox of available reagents for studying CD24 biology across different experimental systems.